TJ Pluard

Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

W. M. Sikov, DA Berry, CM Perou et al. · Cancer Research · 2013 · 55 citations

Medicine, Oncology, Pharmacology +16

AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.

Thomas A. Samuel, Cristiana Sessa, Carolyn D. Britten et al. · Journal of Clinical Oncology · 2010 · 42 citations

Medicine, Oncology, Pharmacology +13

A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603

Eileen M. O’Reilly, Donna Niedzwiecki, Donna Hollis et al. · Journal of Clinical Oncology · 2008 · 24 citations

Medicine, Oncology, Pharmacology +17

Abstract PD07-01: Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 study of Triage to Chemotherapy Based on 2 to 4 week Ki67 level > 10%.

MJ Ellis, Vera J. Suman, Lisa McCall et al. · Cancer Research · 2012 · 14 citations

Medicine, Oncology, Pharmacology +17

A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies

Cristiana Sessa, Sanjeev Sharma, Carolyn D. Britten et al. · Journal of Clinical Oncology · 2009 · 14 citations

Medicine, Oncology, Pharmacology +11